<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00946881</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN901 PCM202</org_study_id>
    <nct_id>NCT00946881</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer</brief_title>
  <official_title>A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steba Biotech S.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steba Biotech S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the optimal treatment conditions (WST11 dose and light
      energy dose) to achieve ablation in one lobe of the prostate and to evaluate the safety and
      quality of life of WST11 medicated Vascular-Targeted Photodynamic therapy (VTP) in men with
      localized prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a multicenter, phase I/II, prospective, open-labeled, single
      intravenous (IV) dose, clinical trial in patients with localized prostate cancer.

      The study population will be men who have been offered curative therapy (radical
      prostatectomy; cryotherapy; brachytherapy; External Beam RadioTherapy (EBRT), and refused.
      Patients must have already had a previous biopsy showing a histologically proven carcinoma of
      the prostate. The identification and the location of the tumor will be done using both
      dynamic contrast Magnetic resonance Imaging (MRI) and biopsy.

      Only unilateral treatment with WST11-medicated VTP will be performed during the study.
      Treatment will consist of a single, 10 minute, IV administration of WST11 at doses of 2mg/kg,
      4 mg/kg or 6 mg/kg, followed by either light activation delivered through transperineal
      interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed
      energy doses of 200 J/cm or 300 J/cm by escalating power at each energy to 167 mW/cm or 250
      mW/cm respectively. A brachytherapy-like template is used for the placement of the
      transparent implant catheters which are positioned in the prostate under transrectal
      ultrasound image guidance. The illumination fiber(s) are then inserted into the implant
      catheters.

      If the safety profile for a given WST11 and light dose is acceptable, additional patients may
      be treated with multiple fibers at that WST11 treatment dose.

      For cases where the Month 6 biopsy is positive, the patient will be offered the opportunity
      to be retreated with WST11
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate Biopsy</measure>
    <time_frame>Month 6</time_frame>
    <description>Arm/Group Title:
WST 11(TOOKAD® Soluble) Arm/Group Description To define the study drug and light dosage combination to achieve negative biopsy in the treated lobe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate Biopsies</measure>
    <time_frame>Month-6</time_frame>
    <description>Number of patients who had a negative biopsy at Month-6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters-Cmax</measure>
    <time_frame>T0, 5 min,10 min, 4 h, 8 h, post dose</time_frame>
    <description>For each dose group, several pharmacokinetics parameters have been calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Prostatic Necrosis at Day 7 as Observed on the 7-Day MRI</measure>
    <time_frame>Day 7</time_frame>
    <description>The adjusted prostate necrosis percentage was defined as follows:
The Day 7 necrosis percentage is the proportion, expressed in %, of Day 7 prostate necrosis volume by planimetry in the treated lobe compared with half the prostate volume by planimetry, considering the average between the baseline volume and Day 7 volume;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Functions (IIEF) Results</measure>
    <time_frame>Month 1-Month 3- Month 6- Month 12</time_frame>
    <description>The International Index of Erectile Functions questionnaire is 15 questions patients auto questionnaire. The results presented are those of the erectile function domain which comprise 6 questions. Possible scores range is 1 to 30 . Best score is 30, worst score is 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (IPSS) Results</measure>
    <time_frame>Month 1, Month 3 , Month 6 , Month 12</time_frame>
    <description>The International Prostate Symptom Score (IPSS) is a 7 questions patients auto-questionnaire about urinary symptoms. the possible scores range are 0 to 35 . Best score is 0 worst score is 35</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters-Tmax</measure>
    <time_frame>T0, 5 min,10 min, 4 h, 8 h, post dose</time_frame>
    <description>For each dose group, several pharmacokinetics parameters have been calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters -T1/2</measure>
    <time_frame>T0, 5 min,10 min, 4 h, 8 h, post dose</time_frame>
    <description>For each dose group, several pharmacokinetics parameters have been calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>WST11 (TOOKAD® Soluble)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WST11-mediated-VTP The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers using 753 nm laser light at escalating fixed energy doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WST 11 -mediated -VTP</intervention_name>
    <description>The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.</description>
    <arm_group_label>WST11 (TOOKAD® Soluble)</arm_group_label>
    <other_name>TOOKAD Soluble</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Diagnosed with localized, prostate cancer and who have been offered curative therapy
             (radical prostatectomy; cryotherapy; brachytherapy; External Beam RadioTherapy (EBRT),
             and refused

          -  Localized prostate cancer stage T1C up to T2A based on biopsy performed at least 6
             weeks prior to enrollment

          -  Gleason score ≤ 3+3 with ≤50% of sampled cores positive, and each positive core having
             a tumour length of ≤5 mm

          -  Prostate Specific Antigen (PSA) &lt; 10 ng/mL

          -  No prior treatment for prostate cancer

          -  Signed Informed Consent Form

        Exclusion Criteria:

          -  Any condition or history of illness or surgery that, in the opinion of the
             investigator and/or the Sponsor, might confound the results of the study or pose
             additional risks to the patient.

          -  All patients whose current pre-operative cardiac evaluation does not show their
             fitness for a procedure requiring general anesthesia;

          -  Patients with a prior history of viral or alcoholic hepatitis, and other patients felt
             to be at risk for hepatotoxicity including concomitant use of potentially hepatotoxic
             medications or dietary supplements;

          -  Patients with a history of inflammatory bowel disease or other factors which may
             increase the risk of fistula formation;

          -  Patients who have received any hormonal manipulation (excluding 5-alpha reductase
             inhibitors) or androgen supplements within the previous 6 months;

          -  Patients previously treated by radiation therapy (external therapy or brachytherapy)
             or chemotherapy or any therapy for prostate cancer;

          -  Patients who have received or are receiving chemotherapy for prostate carcinoma or
             other significant cancer;

          -  Patients who have undergone previous TURP (trans-urethral resection of the prostate);

          -  Patients with a history of urethral stricture disease

          -  Patients with a history of acute urinary retention

          -  Patients who are currently (within 10 days before the treatment procedure) receiving
             any medications having potential photosensitizing effects (e.g. tetracyclines,
             sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics and
             griseofulvin)

          -  Patients who are currently receiving anticoagulant drugs (within 10 days before the
             treatment procedure) (e.g.: coumadin, warfarin)

          -  Patient who stopped long term treatment of acetylsalicylic acid (aspirin) or other
             anti platelets agents within 10 days prior to the treatment procedure;

          -  Patient suspected of Disseminated Intravascular Coagulation (DIC) as defined by the
             presence of three out of the five following criteria: platelets decrease, increase of
             PT, increase of aPTT, fibrinogen decrease, D-Dimer increase; from the normal
             laboratory ranges;

          -  Patient with a history of vasculitis or collagen vascular disease;

          -  History of non compliance with medical therapy and medical recommendations or an
             unwillingness or inability to complete patient self-administered questionnaires;

          -  Participation in a clinical study or receipt of an investigational treatment within
             the past 3 months;

          -  A history of porphyria;

          -  A history of sun hypersensitivity or photosensitive dermatitis;

          -  Renal disorders (blood creatinine &gt; 1.5 x ULN) or known post mictional residue &gt; 150cc

          -  Hepatic disorders (transaminases &gt; ULN, bilirubin &gt; ULN, GGT &gt; ULN). In case of slight
             abnormalities, another exam could be performed. If the results are within normal
             ranges, then the patient can be included;

          -  Hematological disorders (white cells &lt; 2500/mm3, neutrophils &lt; 1500/mm3, platelets, &lt;
             140.000/mm3, Hb ≤ 10 g/dL);

          -  Patients with contra-indication to MRI (such as pace maker, metal prosthesis, etc.).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir Taneja, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, New York University Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA - Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midtown Urology &amp; Midtown Urology Surgical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine- Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Urology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2009</study_first_posted>
  <results_first_submitted>April 20, 2016</results_first_submitted>
  <results_first_submitted_qc>October 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2017</results_first_posted>
  <last_update_submitted>October 2, 2017</last_update_submitted>
  <last_update_submitted_qc>October 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic disease</keyword>
  <keyword>genital neoplasm, male</keyword>
  <keyword>Urogenital neoplasm</keyword>
  <keyword>Genital disease</keyword>
  <keyword>male</keyword>
  <keyword>Male urogenital disease</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasm by site</keyword>
  <keyword>prostatic neoplasm</keyword>
  <keyword>Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The data are available in case report form for each patient</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty patients were included in the study by five different centers in the US. All 30 patients received the entire VTP procedure (first treatment phase).
Two of them discontinued the study prior to Month 12. Eight patients who had positive biopsies at Month 6 entered in the retreatment phase. Only 7 of them actually received retreatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>WST 11(TOOKAD® Soluble)</title>
          <description>WST 11-mediated-VTP
WST 11 -mediated -VTP: The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient relocated to another state</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Retreatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8">This part concerns the number of patients who were retreated ,not the same number as previous period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 30 patients were males suffering from low risk prostate cancer.</population>
      <group_list>
        <group group_id="B1">
          <title>WST 11(TOOKAD® Soluble)</title>
          <description>WST 11-mediated-VTP
WST 11 -mediated -VTP: The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prostate Biopsy</title>
        <description>Arm/Group Title:
WST 11(TOOKAD® Soluble) Arm/Group Description To define the study drug and light dosage combination to achieve negative biopsy in the treated lobe</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 mg/Kg-200 J/cm</title>
            <description>Number of patients with positives or négatives biopsies at the dose 2mg/Kg-200J/cm</description>
          </group>
          <group group_id="O2">
            <title>2 mg/Kg-300 J/cm</title>
            <description>Number of patients with positives or négatives biopsies at the dose 2mg/Kg-300J/cm</description>
          </group>
          <group group_id="O3">
            <title>4 mg/Kg-200 J/cm</title>
            <description>Number of patients with positives or négatives biopsies at the dose 4mg/Kg-200J/cm</description>
          </group>
          <group group_id="O4">
            <title>All Doses/Energies</title>
            <description>Number of patients with positives or négatives biopsies at all doses/energies</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Biopsy</title>
          <description>Arm/Group Title:
WST 11(TOOKAD® Soluble) Arm/Group Description To define the study drug and light dosage combination to achieve negative biopsy in the treated lobe</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prostate Biopsies</title>
        <description>Number of patients who had a negative biopsy at Month-6</description>
        <time_frame>Month-6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 mg/Kg-200 J/cm</title>
            <description>Number of patients with negative biopsies at the dose 2mg/Kg-200J/cm</description>
          </group>
          <group group_id="O2">
            <title>2 mg/Kg-300 J/cm</title>
            <description>Number of patients with negative biopsies at the dose 2mg/Kg-300J/cm</description>
          </group>
          <group group_id="O3">
            <title>4 mg/Kg-200 J/cm</title>
            <description>Number of patients with negative biopsies at the dose 4mg/Kg-200J/cm</description>
          </group>
          <group group_id="O4">
            <title>All Doses/Energies</title>
            <description>Number of patients with negative biopsies at all doses/energies</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Biopsies</title>
          <description>Number of patients who had a negative biopsy at Month-6</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters-Cmax</title>
        <description>For each dose group, several pharmacokinetics parameters have been calculated.</description>
        <time_frame>T0, 5 min,10 min, 4 h, 8 h, post dose</time_frame>
        <population>Out of 30 patients treated in the study, 29 patients had pharmacokinetic data available.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>Patients treated at the dose of 2 mg/kg of TOOKAD soluble, regardless of the dose of light, are analysed in this group.</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>Patients treated at the dose of 4 mg/kg of TOOKAD soluble, regardless of the dose of light, are analysed in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters-Cmax</title>
          <description>For each dose group, several pharmacokinetics parameters have been calculated.</description>
          <population>Out of 30 patients treated in the study, 29 patients had pharmacokinetic data available.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30883.83" spread="11583.07"/>
                    <measurement group_id="O2" value="57102.87" spread="14849.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Prostatic Necrosis at Day 7 as Observed on the 7-Day MRI</title>
        <description>The adjusted prostate necrosis percentage was defined as follows:
The Day 7 necrosis percentage is the proportion, expressed in %, of Day 7 prostate necrosis volume by planimetry in the treated lobe compared with half the prostate volume by planimetry, considering the average between the baseline volume and Day 7 volume;</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 mg/Kg-200 J/cm</title>
            <description>To evaluate the volume of necrosis observed on the 7-Day MRI in patients treated with 2 mg/kg-200J/cm</description>
          </group>
          <group group_id="O2">
            <title>2 mg/Kg-300 J/cm</title>
            <description>To evaluate the volume of necrosis observed on the 7-Day MRI in patients treated with 2 mg/kg-300J/cm</description>
          </group>
          <group group_id="O3">
            <title>4 mg/Kg-200 J/cm</title>
            <description>To evaluate the volume of necrosis observed on the 7-Day MRI in patients treated with 4 mg/kg-200J/cm</description>
          </group>
          <group group_id="O4">
            <title>All Doses/Energies</title>
            <description>To evaluate the volume of necrosis observed on the 7-Day MRI in patients treated with all doses/energies</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Prostatic Necrosis at Day 7 as Observed on the 7-Day MRI</title>
          <description>The adjusted prostate necrosis percentage was defined as follows:
The Day 7 necrosis percentage is the proportion, expressed in %, of Day 7 prostate necrosis volume by planimetry in the treated lobe compared with half the prostate volume by planimetry, considering the average between the baseline volume and Day 7 volume;</description>
          <units>percentage of prostatic necrosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" spread="41.6"/>
                    <measurement group_id="O2" value="13.8" spread="16.3"/>
                    <measurement group_id="O3" value="61.1" spread="25.3"/>
                    <measurement group_id="O4" value="52.3" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Index of Erectile Functions (IIEF) Results</title>
        <description>The International Index of Erectile Functions questionnaire is 15 questions patients auto questionnaire. The results presented are those of the erectile function domain which comprise 6 questions. Possible scores range is 1 to 30 . Best score is 30, worst score is 1.</description>
        <time_frame>Month 1-Month 3- Month 6- Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 mg/Kg-200 J/cm</title>
            <description>To assess the QoL-IIEF in patients treated with the dose 2mg/Kg-200J/cm</description>
          </group>
          <group group_id="O2">
            <title>2 mg/Kg-300 J/cm</title>
            <description>To assess the QoL-IIEF in patients treated with the dose 2mg/Kg-300J/cm</description>
          </group>
          <group group_id="O3">
            <title>4 mg/Kg-200 J/cm</title>
            <description>To assess the QoL-IIEF in patients treated with the dose 4mg/Kg-200J/cm</description>
          </group>
          <group group_id="O4">
            <title>All Doses/Energies</title>
            <description>To assess the QoL-IIEF in patients treated with all doses/energies</description>
          </group>
        </group_list>
        <measure>
          <title>International Index of Erectile Functions (IIEF) Results</title>
          <description>The International Index of Erectile Functions questionnaire is 15 questions patients auto questionnaire. The results presented are those of the erectile function domain which comprise 6 questions. Possible scores range is 1 to 30 . Best score is 30, worst score is 1.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.33" spread="4.73"/>
                    <measurement group_id="O2" value="13.17" spread="8.70"/>
                    <measurement group_id="O3" value="18.80" spread="7.88"/>
                    <measurement group_id="O4" value="17.90" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.33" spread="10.97"/>
                    <measurement group_id="O2" value="14.00" spread="8.92"/>
                    <measurement group_id="O3" value="13.65" spread="8.98"/>
                    <measurement group_id="O4" value="13.79" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.33" spread="4.04"/>
                    <measurement group_id="O2" value="14.17" spread="10.26"/>
                    <measurement group_id="O3" value="14.84" spread="7.91"/>
                    <measurement group_id="O4" value="15.18" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.33" spread="1.53"/>
                    <measurement group_id="O2" value="15.00" spread="9.47"/>
                    <measurement group_id="O3" value="15.29" spread="7.46"/>
                    <measurement group_id="O4" value="15.63" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.67" spread="2.52"/>
                    <measurement group_id="O2" value="6.25" spread="10.50"/>
                    <measurement group_id="O3" value="15.29" spread="8.48"/>
                    <measurement group_id="O4" value="14.48" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Prostate Symptom Score (IPSS) Results</title>
        <description>The International Prostate Symptom Score (IPSS) is a 7 questions patients auto-questionnaire about urinary symptoms. the possible scores range are 0 to 35 . Best score is 0 worst score is 35</description>
        <time_frame>Month 1, Month 3 , Month 6 , Month 12</time_frame>
        <population>IPSS results</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/Kg-200 J/cm</title>
            <description>To assess the QoL-IPSS in patients treated with the dose 2mg/Kg-200J/cm</description>
          </group>
          <group group_id="O2">
            <title>2 mg/Kg-300 J/cm</title>
            <description>To assess the QoL-IPSS in patients treated with the dose 2mg/Kg-300J/cm</description>
          </group>
          <group group_id="O3">
            <title>4 mg/Kg-200 J/cm</title>
            <description>To assess the QoL-IPSS in patients treated with the dose 4mg/Kg-200J/cm</description>
          </group>
          <group group_id="O4">
            <title>All Doses/Energies</title>
            <description>To assess the QoL-IPSS in patients treated with all doses/energies</description>
          </group>
        </group_list>
        <measure>
          <title>International Prostate Symptom Score (IPSS) Results</title>
          <description>The International Prostate Symptom Score (IPSS) is a 7 questions patients auto-questionnaire about urinary symptoms. the possible scores range are 0 to 35 . Best score is 0 worst score is 35</description>
          <population>IPSS results</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.67" spread="8.02"/>
                    <measurement group_id="O2" value="11.67" spread="7.31"/>
                    <measurement group_id="O3" value="8.65" spread="6.82"/>
                    <measurement group_id="O4" value="9.48" spread="6.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.67" spread="9.87"/>
                    <measurement group_id="O2" value="11.00" spread="6.00"/>
                    <measurement group_id="O3" value="10.62" spread="6.34"/>
                    <measurement group_id="O4" value="10.60" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="5.69"/>
                    <measurement group_id="O2" value="8.83" spread="4.83"/>
                    <measurement group_id="O3" value="8.00" spread="5.36"/>
                    <measurement group_id="O4" value="7.83" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.67" spread="8.62"/>
                    <measurement group_id="O2" value="8.50" spread="4.23"/>
                    <measurement group_id="O3" value="6.71" spread="4.80"/>
                    <measurement group_id="O4" value="7.37" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="4.04"/>
                    <measurement group_id="O2" value="15.5" spread="8.89"/>
                    <measurement group_id="O3" value="7.93" spread="4.50"/>
                    <measurement group_id="O4" value="9.29" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters-Tmax</title>
        <description>For each dose group, several pharmacokinetics parameters have been calculated.</description>
        <time_frame>T0, 5 min,10 min, 4 h, 8 h, post dose</time_frame>
        <population>Out of 30 patients treated in the study, 29 patients had pharmacokinetic data available.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>Patients treated at the dose of 2 mg/kg of TOOKAD soluble, regardless of the dose of light, are analysed in this group.</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>Patients treated at the dose of 4 mg/kg of TOOKAD soluble, regardless of the dose of light, are analysed in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters-Tmax</title>
          <description>For each dose group, several pharmacokinetics parameters have been calculated.</description>
          <population>Out of 30 patients treated in the study, 29 patients had pharmacokinetic data available.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.61"/>
                    <measurement group_id="O2" value="0.25" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameters -T1/2</title>
        <description>For each dose group, several pharmacokinetics parameters have been calculated.</description>
        <time_frame>T0, 5 min,10 min, 4 h, 8 h, post dose</time_frame>
        <population>Out of 30 patients treated in the study, 29 patients had pharmacokinetic data available.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg/kg</title>
            <description>Patients treated at the dose of 2 mg/kg of TOOKAD soluble, regardless of the dose of light, are analysed in this group.</description>
          </group>
          <group group_id="O2">
            <title>4 mg/kg</title>
            <description>Patients treated at the dose of 4 mg/kg of TOOKAD soluble, regardless of the dose of light, are analysed in this group.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters -T1/2</title>
          <description>For each dose group, several pharmacokinetics parameters have been calculated.</description>
          <population>Out of 30 patients treated in the study, 29 patients had pharmacokinetic data available.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.90"/>
                    <measurement group_id="O2" value="1.69" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>WST 11(TOOKAD® Soluble)</title>
          <description>WST 11-mediated-VTP The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers using 753 nm laser light at escalating fixed energy doses
WST 11 -mediated -VTP: The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="45" subjects_affected="19" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" events="25" subjects_affected="16" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bertrand Gaillac International Project Leader</name_or_title>
      <organization>STEBA Biotech</organization>
      <phone>+ 33 1 40 72 34 03</phone>
      <email>b.gaillac@stebabiotech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

